SIC
LRMR icon

SJS Investment Consulting’s Larimar Therapeutics LRMR Stock Holding History

SJS Investment Consulting’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18K Buy
386
+355
+1,145% +$1.41K ﹤0.01% 1972
2026
Q1 		$140 Buy
+31
New +$124 ﹤0.01% 2066

Other funds holding LRMR

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return
NLP
Next Level Private Harrison, New York $511M AUM 30.94% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $17.8B AUM 24.16% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SJS Investment Consulting's LRMR Position: Q2 2026 in Review

SJS Investment Consulting increased its Larimar Therapeutics (LRMR) stake by 1,145% in Q2 2026, buying an estimated $1.41K and bringing the position to 386 shares worth $1.18K. The position accounts for ﹤0.01% of the portfolio, ranked #1972.

SJS Investment Consulting first reported a position in LRMR in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • SJS Investment Consulting held 386 shares of Larimar Therapeutics worth $1.18K as of Q2 2026.
  • SJS Investment Consulting bought 355 Larimar Therapeutics shares in Q2 2026, an estimated $1.41K.
  • Larimar Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #1972 holding.
  • SJS Investment Consulting first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.